Xencor earnings date
Xencor (XE9) Q4 2023 Earnings Report
DE:XE9 Q4 2023 EPS Results
- Actual EPS
- -EUR 0.28
- Consensus EPS
- -EUR 0.10
- Beat/Miss
- Missed by -EUR 0.18
- One Year Ago EPS
- -EUR 0.18
DE:XE9 Q4 2023 Revenue Results
- Actual Revenue
- EUR 46.07M
- Expected Revenue
- EUR 70.18M
- Beat/Miss
- Missed by -EUR 24.11M
- YoY Revenue Growth
- +135.84%
Earnings Announcement Details
- Quarter
- Q4 2023
- Date
- 02/27/2024
- Time
- After Close
- Conference Call
- Tuesday, February 27, 2024
Xencor's next earnings date is estimated for February 24, 2027, based on past reporting schedules.
Q4 2023 Earnings Call Audio
Q4 2023 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2023 Earnings Call Summary
The earnings call presented a positive outlook with significant pipeline progress and a strong financial position. However, safety concerns with vudalimab and a strategic pause on XmAb564 development were noted.
During Xencor's fourth-quarter 2023 earnings call, the company provided comprehensive guidance on its clinical pipeline and financial outlook. They highlighted a significant focus on the development of bispecific T-cell engagers for solid tumors, including XmAb819 and XmAb808, with ongoing Phase I studies in renal cell carcinoma and prostate cancer, respectively. Vudalimab, a key candidate, showed promising monotherapy results in heavily pre-treated metastatic castrate-resistant prostate cancer patients, with a RECIST response rate of 35% and a PSA90 rate of 25%. Financially, Xencor bolstered its balance sheet through the partial monetization of Ultomiris and Monjuvi royalties, ending 2023 with $697 million, ensuring operational runway until 2027. The company's 2024 priorities include advancing its solid tumor bispecific programs and selecting the next IND candidate, while maintaining a strategic focus on T-cell engager discovery and development.
- Strong Financial PositionXencor ended 2023 with $697 million, providing runway into 2027 due to robust milestone and royalty revenues.
- Clinical Pipeline ProgressSignificant advancement in bispecific T-cell engagers for solid tumors, including vudalimab in prostate and lung cancer.
- Encouraging Vudalimab DataThe prostate cancer monotherapy cohort showed a RECIST response rate of 35% and a disease control rate of 50%.
- XmAb Bispecific Technology DevelopmentXmAb bispecific technology shows promise for solid tumor selectivity, with ongoing studies in renal and prostate cancer.
DE:XE9 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 24, 2027 | 2026 (Q4) | -0.71- | -0.08 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | -0.300.45 | -0.07 | 725.00% (+0.52) | |
| Aug 05, 2026 | 2026 (Q2) | -0.72-0.26 | -0.37 | 29.27% (+0.11) | |
| May 06, 2026 | 2026 (Q1) | -0.75-1.55 | -0.6 | -159.09% (-0.95) | |
| Feb 25, 2026 | 2025 (Q4) | -0.54-0.08 | -0.56 | 85.48% (+0.48) | |
| Nov 05, 2025 | 2025 (Q3) | -0.62-0.07 | -0.64 | 88.73% (+0.57) | |
| Aug 06, 2025 | 2025 (Q2) | -0.65-0.37 | -0.97 | 61.68% (+0.60) | |
| May 07, 2025 | 2025 (Q1) | -0.53-0.60 | -1 | 40.54% (+0.41) | |
| Feb 27, 2025 | 2024 (Q4) | -0.71-0.56 | -0.28 | -100.00% (-0.28) | |
| Nov 07, 2024 | 2024 (Q3) | -0.89-0.64 | -0.36 | -77.50% (-0.28) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

